GLP-1 and incretin signaling

There are 1,990 papers on GLP-1 and incretin signaling in aging research: 292 trials and 282 observational studies in people, 178 in animals, 25 in cells, 1,113 reviews.

Process

1,990 papers study it4 more mention it15 findings

228 new papers in 30 daysSee all 1,994 papers on GLP-1 and incretin signaling

At a glance

A human study reports no effect of GLP-1 and incretin signaling on estimated bone mineral density, while a mouse study shows activation by Citrus changshan huyou extract in the intestine. Reviews link the pathway to the incretin effect, reduced cardiovascular disease and lower body weight in humans; no independently replicated change is reported.

15 findings in 14 papers from 2016 to 2026, 6 of them since August 2026

The findings reach people, from one lab or study. 4 independent labs in 4 countries.

None of its findings points the other way.

Mice and humans: a single group. Cells and worms or flies: nothing yet.
  • 4 independent labs in 4 countries
  • Funders: Chinese Academy of Sciences and others
  • Human trial292
  • Humans282
  • Animals177
  • Model organisms1
  • Cells25
  • In silico23

Interventions

3

Sleeve gastrectomy

upin humans1

1 study
  1. Sleeve gastrectomy activates GLP-1 and incretin signaling in humans (severe obesity without diabetes).

    “both groups exhibiting enhanced secretion of GLP-1 and GLP-2 following MTT”

    Human trialsevere obesity without diabetes6 monthsn = 18

    Insulin resistance modulates gut microbiota and incretin response remodeling after bariatric surgery in severe obesity

    International journal of obesity (2005)

More on Sleeve gastrectomy

Tirzepatide

upin reviews1

1 study
  1. Tirzepatide activates GLP-1 and incretin signaling.

    “Tirzepatide is a novel "twincretin" that functions as a dual glucose-dependent insulinotropic polypeptide and GLP-1 RA.”

    Review

    Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?

    Cardiology in review

More on Tirzepatide

Caloric restriction

upin mice1

1 study
  1. Caloric restriction activates GLP-1 and incretin signaling in db/db mice.

    “GLP-1 pathway was reactivated with long-term CR.”

    Animalsin db/db mice

    Reversibility of β-Cell-Specific Transcript Factors Expression by Long-Term Caloric Restriction in db/db Mouse

    Journal of diabetes research

More on Caloric restriction

Effects

6

Glucose-dependent insulin secretion

upin reviews1

1 study
  1. GLP-1 and incretin signaling increases glucose-dependent insulin secretion (diabetes mellitus).

    “GLP-1 signaling and DPP-4 inhibition improve glucose-dependent insulin secretion while supporting β-cell survival and function.”

    Reviewdiabetes mellituspancreatic beta cell

    Mechanistic Insights into GLP-1 and DPP-4 Pathways: Opportunities for Nano-Delivery and β-Cell Protection and Regeneration

    Current diabetes reviews

Cardiovascular disease

downin humans1

1 study
  1. GLP-1 and incretin signaling decreases cardiovascular disease in humans.

    “Obesity-related disease processes including type 2 diabetes mellitus, cardiovascular disease, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, and obstructive sleep apnea improve in patients treated with these medications”

    Review

    The Incretin Revolution: Integrating Incretin-Based Therapies into Clinical Care

    Biomedical journal

More on Cardiovascular disease

Body weight

downin humans1

1 study
  1. GLP-1 and incretin signaling decreases body weight in humans.

    “producing substantial weight loss and benefits across cardiometabolic outcomes.”

    Review

    Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement

    The Lancet regional health. Europe

Tumor growth

upin reviews1

1 study
  1. GLP-1 and incretin signaling increases tumor growth in select receptor-expressing models.

    “GLP-1 receptor activation may promote tumor growth in select receptor-expressing models”

    Reviewin select receptor-expressing models

    Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement

    Cancer

Bone

upin humans1

1 study
  1. GLP-1 and incretin signaling improves bone in patients with diabetes mellitus.

    “therapies that are based on incretin effect, like Dipeptidyl peptidase-4 inhibitors (DPP-4i) and Glucagon-like peptide-1 receptor agonizts (GLP-1RAs) might have positive effects on bone health by promoting bone formation.”

    Reviewin patients with diabetes mellitusbone

    The effect of antidiabetic drugs on bone metabolism: a concise review

    Endocrine

Insulin secretion

mediatesin humans1

1 study
  1. GLP-1 and incretin signaling mediates insulin secretion in humans after RYGBP.

    “The improvement in insulin secretion rate and β-cell sensitivity to oral glucose after RYGBP is mediated by endogenous GLP-1”

    Reviewafter RYGBP

    Bariatric surgery and obesity: influence on the incretins

    International journal of obesity supplements

Upstream

1

Circadian misalignment

downin reviews1

1 study
  1. circadian misalignment impairs GLP-1 and incretin signaling (from shift work, nocturnal light exposure, and sleep loss).

    “the vulnerability of incretin rhythms to circadian misalignment from shift work, nocturnal light exposure, and sleep loss”

    Reviewfrom shift work, nocturnal light exposure, and sleep loss

    GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease

    International journal of molecular sciences

Associations

5

Diet quality

mixedin humans1

1 study
  1. Diet quality is associated with GLP-1 and incretin signaling in humans.

    “Evidence consistently demonstrated that dietary quality influences endogenous GLP-1 signaling through nutrient-mediated secretion, gut microbiome-derived metabolites, inflammatory pathways, and metabolic regulation.”

    Review

    Diet Quality as an Unrecognized Effect Modifier of GLP-1 Receptor Agonist Cardiovascular Outcomes: A Systematic Review and Translational Framework

    AHA Scientific Sessions 2026 abstract

More on Diet quality

Incretin effect

mixedin humans1

1 study
  1. GLP-1 and incretin signaling is associated with incretin effect in humans.

    “elevated GLP-1 coexists with an impaired incretin effect because it is compensation for β-cell failure”

    Review

    Rise or fall? Reconciling contested directions in human gut hormone aging

    Frontiers in endocrinology

Circadian clock

no changein reviews1

1 study
  1. GLP-1 and incretin signaling is associated with circadian clock.

    “Emerging data suggest that GLP-1 signaling is under circadian regulation and may, in turn, influence central and peripheral clock systems.”

    Review

    GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease

    International journal of molecular sciences

More on Circadian clock

Inflammation

mixedin reviews1

1 study
  1. GLP-1 and incretin signaling is associated with inflammation in Parkinson's disease models, convergence with proteostasis and mitochondrial homeostasis.

    “We consolidate evidence across PI3K/Akt, MAPK/ERK, cAMP/PKA-CREB, and AMPK pathways, emphasising their convergence on mitochondrial homeostasis, proteostasis, neuroinflammation, and synaptic resilience.”

    Reviewin Parkinson's disease models, convergence with proteostasis and mitochondrial homeostasis

    GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review

    International journal of molecular sciences

More on Inflammation

Metformin

mixedin humans1

1 study
  1. Metformin is associated with GLP-1 and incretin signaling in the gut.

    “In the gut, metformin modulates the glucagon-like peptide- 1 (GLP-1) - gut-brain axis and impacts the intestinal microbiota.”

    Reviewin the gutgut

    Repurposing Metformin for Vascular Disease

    Current medicinal chemistry

More on Metformin

Funding

171 grants since 2016

National Institute of Diabetes and Digestive and Kidney Diseases$31.2MJapan Society for the Promotion of Science¥113MNational Heart, Lung, and Blood Institute$8.2M

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 55Jan 2026: 184Feb 2026: 190Mar 2026: 141Apr 2026: 42May 2026: 36Jun 2026: 80Jul 2026: 79Aug 2026: 73Sep 2026: 95Oct 2026: 141Nov 2026: 1001,216 papers in 12 months

See all 1,994 papers on GLP-1 and incretin signaling